TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

NCT00896051 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections
Acquired Immunodeficiency Syndrome

Interventions

DRUG: Atazanavir (ATV) 300 mg
DRUG: Atazanavir (ATV) 400 mg
DRUG: Ritonavir (rtv) 100 mg
DRUG: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)
DRUG: Etravirine (ETR) 200 mg
DRUG: Tenofovir disoproxil fumarate (TDF) 300 mg

Sponsor

Janssen R&D Ireland